Is CML curable with imatinib?
Is CML curable with imatinib?
Imatinib mesylate has transformed the treatment for chronic myeloid leukemia (CML). The vast majority of patients obtain hematologic remission, with a low probability of progression of disease. Yet imatinib rarely cures CML, and current recommendations dictate lifelong treatment with imatinib.
How effective is imatinib for CML?
An overall survival (OS) rate is 85% for patients receiving imatinib (93% when only CML- related deaths and those prior to stem cell transplantation are considered), with the annual rates of progression to AP or BC in year 4 to 8 after imatinib therapy onset are: 0.9%, 0.5%, 0%, 0%, and 0.4%, respectively.
How long is imatinib taken CML?
The median duration of first-line imatinib therapy was 8.9 years (range, <0.1 to 11.7). Enrollment and Randomization of Patients and Censoring of Data for the Analysis of Overall Survival at 10 Years.
How long do you take imatinib?
Optimal duration of therapy is unknown but generally imatinib should be continued for 6–9 months, after which additional tumor shrinkage is usually minor.
Can you stop taking imatinib?
Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia (CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years. We report the final results of the Stop Imatinib (STIM1) study with a long follow-up.
What is the success rate of imatinib?
Among the patients in the imatinib group, the estimated overall survival rate at 10 years was 83.3%. Approximately half the patients (48.3%) who had been randomly assigned to imatinib completed study treatment with imatinib, and 82.8% had a complete cytogenetic response.
How quickly does imatinib work?
Using RECIST, the median time to response is approximately 3 months, and median time to disease progression on imatinib is about 2 years.
How long can you take imatinib?
How long does CML treatment last?
The chronic phase varies in duration, depending on the maintenance therapy used: it usually lasts 2-3 years with hydroxyurea (Hydrea) or busulfan therapy, but it may last for longer than 9.5 years in patients who respond well to interferon-alfa therapy.
How is imatinib used to treat chronic myeloid leukemia?
Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy.
Are there any phase 3 trials for imatinib?
Phase III trials An International Randomized Study of Interferon and STI571 (IRIS) comparing imatinib at a single daily dose 400 mg to IFN alpha plus cytarabine in newly diagnosed patients with CML in CP was initiated in June 2000.
Which is better for CML interferon alfa or imatinib?
Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa. We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML.
How does imatinib bind to Bcr-Abl kinase?
Imatinib binds to BCR-ABL kinase domain by preventing the transfer of a phosphate group to tyrosine on the protein substrate and the subsequent activation of phosphorylated protein. As the result, the transmission of proliferative signals to the nucleus is blocked and leukemic cell apoptosis is induced.